ATP5A1 Gene

📖 Wiki Page

gene1028 wordssynced 2026-04-02

ATP5A1 — ATP Synthase Subunit Alpha

Introduction

Atp5A1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@brown2014]
<table>
<tr><th colspan="2" style="background:#1a5f7a;color:white;">ATP5A1 — ATP Synthase Subunit Alpha</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ATP5A1</td></tr>
<tr><td><strong>Full Name</strong></td><td>ATP Synthase Subunit Alpha</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>21q21.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[498](https://www.ncbi.nlm.nih.gov/gene/498)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000188039</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P25788](https://www.uniprot.org/uniprot/P25788)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Mitochondrial Dysfunction](/diseases/mitochondrial-dysfunction)</td></tr>
</table>
</div>

Overview

...

ATP5A1 — ATP Synthase Subunit Alpha

Introduction

Atp5A1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

ATP5A1 encodes the alpha subunit of mitochondrial ATP synthase (Complex V), the enzyme responsible for synthesizing ATP from ADP using the proton gradient across the inner mitochondrial membrane. This is the final step of oxidative phosphorylation.

ATP5A1 is one of the most abundant mitochondrial proteins and is essential for:

ATP production via oxidative phosphorylation
Mitochondrial function maintenance
Cellular energy homeostasis

Molecular Mechanism

The mitochondrial ATP synthase (Complex V) is a large multiprotein complex consisting of over 20 subunits. ATP5A1 (encoded by nuclear DNA but imported into mitochondria) forms the central catalytic alpha subunit of the F1 domain. [@moree2023]

The enzymatic mechanism involves:

Proton Gradient Utilization: The F0 portion of the complex spans the inner mitochondrial membrane and acts as a proton channel. Protons flowing back through F0 drive the rotation of the central shaft.

Rotary Catalysis: The gamma subunit rotates within the alpha3beta3 hexamer of the F1 domain, causing conformational changes that drive ATP synthesis from ADP and inorganic phosphate (Pi).

Coupling Efficiency: ATP5A1's function is directly coupled to the electron transport chain (ETC). Any disruption in ETC complex I-IV activity reduces the proton gradient, compromising ATP synthesis capacity.

Structural Details

Protein Size: 553 amino acids, ~60 kDa
Topology: Matrix-facing F1 domain
Oligomeric State: Forms part of the alpha3beta3 hexamer with 3 alpha (ATP5A1) and 3 beta (ATP5B) subunits
Post-translational Modifications: Known to be phosphorylated and acetylated, affecting enzyme activity and assembly

Function

ATP Synthesis

Catalyzes ATP synthesis from ADP and Pi
Uses proton motive force generated by ETC
F1 portion contains alpha3beta3hexamer - catalytic core

Structure

~553 amino acids
Molecular weight ~60 kDa
Located in mitochondrial matrix
Part of the F1 catalytic domain

Regulation

Oligomycin sensitivity conferral protein (OSCP) interaction
Inhibitory proteins (IF1) regulation
ADP/ATP exchange via adenine nucleotide translocase
Transcriptional regulation by PGC-1alpha (mitochondrial biogenesis master regulator)

Disease Associations

Alzheimer's Disease

Alzheimer's disease (AD) is characterized by progressive cognitive decline accompanied by neuronal loss and synaptic dysfunction. Mitochondrial dysfunction is now recognized as an early event in AD pathogenesis, with ATP5A1 playing a central role. [@brown2014]

Evidence from Human Studies:

Reduced ATP5A1 protein expression in AD prefrontal cortex [@wang2022]
Decreased ATP synthase activity in AD temporal gyrus
Correlation between reduced Complex V activity and MMSE scores
Altered ATP5A1 phosphorylation patterns in AD brain

Mechanistic Links:

Amyloid-beta (Aβ) oligomers directly inhibit mitochondrial ATP synthase activity
Tau pathology disrupts mitochondrial dynamics, affecting ATP synthase assembly
Oxidative stress in AD damages ATP5A1 through carbonylation
[Microglia](/cell-types/microglia)mediated neuroinflammation reduces neuronal ATP5A1 expression

Therapeutic Implications:

Agents that enhance ATP synthase efficiency
PGC-1alpha agonists to boost mitochondrial biogenesis
Antioxidants to protect ATP5A1 from oxidative damage

Parkinson's Disease

Parkinson's disease (PD) features selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. These neurons have particularly high energy demands, making them vulnerable to mitochondrial dysfunction. [@cheng2021]

Mitochondrial Complex I Deficiency:

The most consistent biochemical finding in PD substantia nigra
Reduced Complex I activity leads to decreased proton pumping
Compromised proton gradient limits ATP synthase capacity
ATP5A1 expression is downregulated in PD brains

Mechanistic Links:

LRRK2 mutations (common in familial PD) affect mitochondrial function
Alpha-synuclein aggregation disrupts mitochondrial membranes
PINK1/Parkin mitophagy pathway dysfunction
Environmental toxins (MPTP, rotenone) inhibit Complex I

Therapeutic Implications:

CoQ10 supplementation to support electron flow
ATP5A1 expression modulators
Mitochondrial turnover enhancers

Mitochondrial Disorders

Mutations in ATP5A1 cause rare but severe mitochondrial disorders: [@moree2023]

ATP Synthase Deficiency: Reduced enzyme activity
Mitochondrial Encephalomyopathy: Combined neurological and muscular symptoms
Lactic Acidosis: Due to impaired oxidative phosphorylation
Developmental Delay: In pediatric cases
Hypertrophic Cardiomyopathy: Due to high cardiac energy demands

Amyotrophic Lateral Sclerosis (ALS)

Emerging evidence suggests ATP5A1 dysfunction may contribute to ALS pathogenesis:

Motor neurons have exceptionally high energy requirements
Mitochondrial dysfunction is observed in ALS spinal cord
ATP5A1 aggregates have been reported in ALS models

Therapeutic Targets

Drug Development Approaches

| Target | Approach | Status |
|--------|----------|--------|
| ATP synthase activators | Small molecule enhancers | Preclinical |
| PGC-1alpha agonists | Increase mitochondrial biogenesis | Clinical trials |
| Antioxidants | Protect against ROS damage | Clinical trials |
| Mitochondrial stabilizers | Prevent fission/fusion defects | Preclinical |

Nutritional Interventions

Coenzyme Q10: Supports electron transport chain
L-carnitine: Enhances mitochondrial fatty acid transport
Alpha-lipoic acid: Antioxidant and mitochondrial support
Creatine: Helps maintain cellular ATP pools

Expression Pattern

ATP5A1 is ubiquitously expressed with tissue-specific levels: [@wang2022]

Brain: High in pyramidal neurons of [cortex](/brain-regions/cortex) and [hippocampus](/brain-regions/hippocampus)
Heart: Very high (continuous energy demand for contractile function)
Skeletal Muscle: High in fast-twitch fibers
Liver: High metabolic activity
Kidney: Energy-intensive transport processes

Cellular Localization

Primary: Mitochondrial inner membrane (F1 domain facing matrix)
Secondary: May associate with mitochondrial nucleoids
Distribution: Approximately 10-15% of total mitochondrial protein mass

Background

The study of Atp5A1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[NCBI Gene - ATP5A1](https://www.ncbi.nlm.nih.gov/gene/498)
[UniProt - ATP5A1](https://www.uniprot.org/uniprot/P25788)
[Ensembl - ATP5A1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188039)

References

[Cadenas et al., Mitochondrial ATP synthesis in neurodegeneration (2010)](https://doi.org/10.1016/j.tibs.2010.05.004)

[Brown et al., ATP synthase and Alzheimer's disease (2014)](https://doi.org/10.1016/j.neurobiolaging.2013.12.001)

[Moree et al., Mitochondrial ATP synthase dysfunction in neurodegenerative diseases (2023)](https://doi.org/10.1016/j.nbd.2023.105879)

[Wang et al., ATP5A1 expression in Alzheimer's disease brain (2022)](https://doi.org/10.1038/s41598-022-15642-4)

[Cheng et al., Targeting mitochondrial ATP synthase in Parkinson's disease (2021)](https://doi.org/10.1016/j.bbadis.2021.166123)

Pathway Diagram

The following diagram shows the key molecular relationships involving ATP5A1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →